Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kang Stem Biotech Co., Ltd.
This is a observational study, single center, open label, study of safety of FURESTEM-RA Inj. in subjects with moderate to severe rheumatoid arthritis.
Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.
\[NCT02221258\]
Age
19–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.\[NCT02221258\]
Subject who understands and voluntarily sign an informed consent form
You may not be if
In case follow-up is not possible from end of clinical trial Phase 1 to end of this study period
Clareo Health | Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj
